Stellar Biotechnologies Signs KLH Supply Agreement with Biovest International

Stellar Biotechnologies Inc. (OTCQB:SBOTF,TSXV:KLH) has executed a definitive supply agreement with Biovest International for Biovest’s Keyhole Limpet Hemocyanin (KLH). KLH is meant to be used in Biovest’s BiovaxID® active immunotherapy to treat follicular non-Hodgkin’s lymphoma.

As quoted in the press release:

The purpose of the supply agreement is to establish the terms for the production and supply of Stellar KLH™ to Biovest, for use as an active component in BiovaxID® immunotherapy vaccine in both commercial distribution as well as for future clinical trials.

The supply agreement requires Stellar to deliver Stellar KLH™ to Biovest compliant with cGMP standards required for Biovest’s ongoing development and as an anticipated commercial supply. Biovest is obligated to purchase Stellar KLH™ at agreed forecasted quantities and prices. The supply agreement has an initial three-year term, which may be renewed by Biovest for additional one-year periods.

Stellar president and CEO, Frank Oakes, said:

Stellar’s key growth initiative is to leverage our Stellar KLH™ technology into multiple clinical pathways and the BiovaxID® program is a good example of the value of our core business for this purpose. There are many new KLH-based immunotherapies advancing in clinical trials and we are positioning Stellar to be the leading company capable of delivering the scalable, sustainable supplies of KLH that will be needed by these pharmaceutical pipelines.

Click here to read the Stellar Biotechnologies Inc. (OTCQB:SBOTF,TSXV:KLH) press release